TapewireFind a company

person · Reporting owner

Hughes Douglas J.

Disclosed activity across 2 companies

Tapewire entity
53086
SEC CIK
0001710863

Export transaction history ↓

Reported relationships

Latest disclosed role at each company.

CompanyLast reported asReport datePublished
Eargo, Inc.EAR · Entity 94112DirectorNovember 22, 2022November 25, 2022
Immunovant, Inc.IMVT · Entity 3632DirectorApril 07, 2026April 09, 2026

Disclosed balances

About these balances

Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.

Eargo, Inc.

Report date November 22, 2022 · Filed November 25, 2022

Security / awardOwnership accountDisclosed shares / unitsDisclosure context
Common StockSEC Table I · non-derivativeDirect107,072 Reported balance After 2022-11-22 transaction · row 1
1 source row

Row 1 · 2022-11-22 · Other · Acquired 71,363 · Balance 107,072

F1: Represents shares of the Issuer's Common Stock acquired by the Reporting Person following the exercise of his basic subscription rights in connection with the Issuer's rights offering to holders of Common Stock, as described in the issuer's prospectus dated October 27, 2022 (the "Rights Offering"). Each holder of Common Stock of record as of October 24, 2022 received one right for each share of Common Stock, and each right entitled the holder of Common Stock to purchase 9.5151 shares of Common Stock at the subscription price of $0.50 per whole share.

Subscription Rights (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.50Direct0 Reported balance After 2022-11-23 transaction · row 2 Instrument identity requires review; Table II rows are not merged.
1 source row

Row 2 · 2022-11-23 · Other · Disposed 7,500 · Balance 0

F2: Represents exercise price per whole share of Common Stock.

F3: The Rights Offering expired on November 17, 2022, and final determination of the pro rata allocation for each exercising holder was determined on November 22, 2022.

Filing footnotes · ownership attribution and instrument terms

F1: Represents shares of the Issuer's Common Stock acquired by the Reporting Person following the exercise of his basic subscription rights in connection with the Issuer's rights offering to holders of Common Stock, as described in the issuer's prospectus dated October 27, 2022 (the "Rights Offering"). Each holder of Common Stock of record as of October 24, 2022 received one right for each share of Common Stock, and each right entitled the holder of Common Stock to purchase 9.5151 shares of Common Stock at the subscription price of $0.50 per whole share.

F2: Represents exercise price per whole share of Common Stock.

F3: The Rights Offering expired on November 17, 2022, and final determination of the pro rata allocation for each exercising holder was determined on November 22, 2022.

Immunovant, Inc.

Report date April 07, 2026 · Filed April 09, 2026

Security / awardOwnership accountDisclosed shares / unitsDisclosure context
Common StockSEC Table I · non-derivativeDirect134,653 Reported balance After 2026-04-07 transaction · row 1
1 source row

Row 1 · 2026-04-07 · Grant · Acquired 13,880 · Balance 134,653

F1: These restricted stock units ("RSUs") were granted pursuant to the Issuer's 2019 Equity Incentive Plan (the "Plan"). Each RSU represents a contingent right to receive one share of common stock upon the vesting of the unit. The RSUs will vest in full on April 1, 2027, subject to the Reporting Person's continuous service to the Issuer as of such date. The Reporting Person may elect to defer settlement of the RSUs upon vesting, subject to the requirements of Rule 409A.

Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $24.61 · Expires 2036-04-07Direct7,061 Reported balance After 2026-04-07 transaction · row 2 Instrument identity requires review; Table II rows are not merged.
1 source row

Row 2 · 2026-04-07 · Grant · Acquired 7,061 · Balance 7,061

F2: These options were granted pursuant to the Plan. The shares underlying the options will vest on April 1, 2027, subject to the Reporting Person's continuous service to the Issuer as of such date.

Filing footnotes · ownership attribution and instrument terms

F1: These restricted stock units ("RSUs") were granted pursuant to the Issuer's 2019 Equity Incentive Plan (the "Plan"). Each RSU represents a contingent right to receive one share of common stock upon the vesting of the unit. The RSUs will vest in full on April 1, 2027, subject to the Reporting Person's continuous service to the Issuer as of such date. The Reporting Person may elect to defer settlement of the RSUs upon vesting, subject to the requirements of Rule 409A.

F2: These options were granted pursuant to the Plan. The shares underlying the options will vest on April 1, 2027, subject to the Reporting Person's continuous service to the Issuer as of such date.

Transaction history

JSON API
Reset

Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”

The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.

Transaction dateCompanyActivity / securityShares / unitsReported priceReported valueDetails
April 07, 2026 Filed Apr 9, 2026 20:26 UTC Immunovant, Inc. IMVT · Entity 3632 GrantStock Option (right to buy) · Derivative 7,061 $0.00 Strike: $24.61 $0.00
Disclosure

SEC source: 0001764013-26-000048 · wk-form4_1775766410.xml · derivative · entry 2

Hughes Douglas J. · CIK 0001710863 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 7,061

Underlying: Common Stock · 7,061 shares

Expires 2036-04-07

F2 · derivative.exercise_date: These options were granted pursuant to the Plan. The shares underlying the options will vest on April 1, 2027, subject to the Reporting Person's continuous service to the Issuer as of such date.

Read SEC document
April 07, 2026 Filed Apr 9, 2026 20:26 UTC Immunovant, Inc. IMVT · Entity 3632 GrantCommon Stock 13,880 $0.00 $0.00
Disclosure

SEC source: 0001764013-26-000048 · wk-form4_1775766410.xml · nonDerivative · entry 1

Hughes Douglas J. · CIK 0001710863 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 134,653

F1 · shares: These restricted stock units ("RSUs") were granted pursuant to the Issuer's 2019 Equity Incentive Plan (the "Plan"). Each RSU represents a contingent right to receive one share of common stock upon the vesting of the unit. The RSUs will vest in full on April 1, 2027, subject to the Reporting Person's continuous service to the Issuer as of such date. The Reporting Person may elect to defer settlement of the RSUs upon vesting, subject to the requirements of Rule 409A.

Read SEC document
December 01, 2025 Filed Dec 3, 2025 23:14 UTC Immunovant, Inc. IMVT · Entity 3632 SaleCommon Stock 1,909 $23.96 $45,739.64
Disclosure

SEC source: 0001764013-25-000159 · wk-form4_1764803660.xml · nonDerivative · entry 2

Hughes Douglas J. · CIK 0001710863 · Director

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 120,773

F1 · shares: The sale of shares of common stock reported on this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on February 14, 2025 in order to satisfy applicable tax obligations arising in connection with the vesting and deferred settlement of a prior award of restricted stock units.

F3 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $23.75 - $24.13 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4.

Read SEC document
December 01, 2025 Filed Dec 3, 2025 23:14 UTC Immunovant, Inc. IMVT · Entity 3632 SaleCommon Stock 13,091 $23.14 $302,925.74
Disclosure

SEC source: 0001764013-25-000159 · wk-form4_1764803660.xml · nonDerivative · entry 1

Hughes Douglas J. · CIK 0001710863 · Director

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 122,682

F1 · shares: The sale of shares of common stock reported on this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on February 14, 2025 in order to satisfy applicable tax obligations arising in connection with the vesting and deferred settlement of a prior award of restricted stock units.

F2 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $22.75 - $23.73 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4.

Read SEC document
April 01, 2025 Filed Apr 3, 2025 20:43 UTC Immunovant, Inc. IMVT · Entity 3632 GrantStock Option (right to buy) · Derivative 7,600 $0.00 Strike: $15.20 $0.00
Disclosure

SEC source: 0001764013-25-000045 · wk-form4_1743712974.xml · derivative · entry 2

Hughes Douglas J. · CIK 0001710863 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 7,600

Underlying: Common Stock · 7,600 shares

Expires 2035-04-01

F2 · derivative.exercise_date: The shares underlying the options will vest on April 1, 2026, subject to the Reporting Person's continuous service to the Issuer as of such date.

Read SEC document
April 01, 2025 Filed Apr 3, 2025 20:43 UTC Immunovant, Inc. IMVT · Entity 3632 GrantCommon Stock 16,188 $0.00 $0.00
Disclosure

SEC source: 0001764013-25-000045 · wk-form4_1743712974.xml · nonDerivative · entry 1

Hughes Douglas J. · CIK 0001710863 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 135,773

F1 · shares: These restricted stock units ("RSUs") were granted pursuant to the Issuer's 2019 Equity Incentive Plan. Each RSU represents a contingent right to receive one share of common stock upon the vesting of the unit. The RSUs will vest in full on April 1, 2026, subject to the Reporting Person's continuous service to the Issuer as of such date. The Reporting Person may elect to defer settlement of the RSUs upon vesting, subject to the requirements of Rule 409A.

Read SEC document
December 02, 2024 Filed Dec 4, 2024 21:20 UTC Immunovant, Inc. IMVT · Entity 3632 SaleCommon Stock 5,425 $28.54 $154,829.50
Disclosure

SEC source: 0001764013-24-000199 · wk-form4_1733347209.xml · nonDerivative · entry 1

Hughes Douglas J. · CIK 0001710863 · Director

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 119,585

F1 · shares: The sale of shares of common stock reported on this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 16, 2023 in order to satisfy applicable tax obligations arising in connection with the vesting and deferred settlement of a prior award of restricted stock units.

F2 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $28.05 - $28.99 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4.

Read SEC document
April 02, 2024 Filed Apr 4, 2024 20:50 UTC Immunovant, Inc. IMVT · Entity 3632 GrantStock Option (right to buy) · Derivative 4,690 $0.00 Strike: $30.78 $0.00
Disclosure

SEC source: 0001764013-24-000065 · wk-form4_1712263802.xml · derivative · entry 2

Hughes Douglas J. · CIK 0001710863 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 4,690

Underlying: Common Stock · 4,690 shares

Expires 2034-04-02

F2 · derivative.exercise_date: The shares underlying the options will vest on April 2, 2025, subject to the Reporting Person's continuous service to the Issuer as of such date.

Read SEC document
April 02, 2024 Filed Apr 4, 2024 20:50 UTC Immunovant, Inc. IMVT · Entity 3632 GrantCommon Stock 11,255 $0.00 $0.00
Disclosure

SEC source: 0001764013-24-000065 · wk-form4_1712263802.xml · nonDerivative · entry 1

Hughes Douglas J. · CIK 0001710863 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 125,010

F1 · shares: These restricted stock units ("RSUs") were granted pursuant to the Issuer's 2019 Equity Incentive Plan. Each RSU represents a contingent right to receive one share of common stock upon the vesting of the unit. The RSUs will vest in full on April 2, 2025, subject to the Reporting Person's continuous service to the Issuer as of such date. The Reporting Person may elect to defer settlement of the RSUs upon vesting, subject to the requirements of Rule 409A.

Read SEC document
April 12, 2023 Filed Apr 14, 2023 20:35 UTC Immunovant, Inc. IMVT · Entity 3632 GrantStock Option (right to buy) · Derivative 16,260 $0.00 Strike: $14.70 $0.00
Disclosure

SEC source: 0001764013-23-000046 · wf-form4_168150451547406.xml · derivative · entry 2

Hughes Douglas J. · CIK 0001710863 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 16,260

Underlying: Common Stock · 16,260 shares

Expires 2033-04-12

F3 · derivative.exercise_date: The shares underlying the options vest one year after the date of grant on April 12, 2024, subject to the Reporting Person's continuous service to the Issuer as of such date.

Read SEC document
April 12, 2023 Filed Apr 14, 2023 20:35 UTC Immunovant, Inc. IMVT · Entity 3632 GrantCommon Stock 12,523 $0.00 $0.00
Disclosure

SEC source: 0001764013-23-000046 · wf-form4_168150451547406.xml · nonDerivative · entry 1

Hughes Douglas J. · CIK 0001710863 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 113,755

F1 · security: Represents the number of shares underlying restricted stock units awards ("RSUs").

F2 · shares: The RSUs vest in their entirety one year after the date of grant on April 12, 2024, subject to the Reporting Person's continued service to the Issuer as of such date; provided that the Reporting Person may elect to defer settlement of the RSUs upon vesting, subject to the requirements of Rule 409A.

Read SEC document
November 23, 2022 Filed Nov 25, 2022 18:05 UTC Eargo, Inc. EAR · Entity 94112 OtherSubscription Rights (right to buy) · Derivative 7,500 $0.00 Strike: $0.50 $0.00
Disclosure

SEC source: 0000899243-22-037001 · doc4.xml · derivative · entry 2

Hughes Douglas J. · CIK 0001710863 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 71,363 shares

Expires not disclosed

F2 · derivative.exercise_price: Represents exercise price per whole share of Common Stock.

F3 · derivative.expiration_date: The Rights Offering expired on November 17, 2022, and final determination of the pro rata allocation for each exercising holder was determined on November 22, 2022.

Read SEC document
November 22, 2022 Filed Nov 25, 2022 18:05 UTC Eargo, Inc. EAR · Entity 94112 OtherCommon Stock 71,363 $0.50 $35,681.50
Disclosure

SEC source: 0000899243-22-037001 · doc4.xml · nonDerivative · entry 1

Hughes Douglas J. · CIK 0001710863 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 107,072

F1 · shares: Represents shares of the Issuer's Common Stock acquired by the Reporting Person following the exercise of his basic subscription rights in connection with the Issuer's rights offering to holders of Common Stock, as described in the issuer's prospectus dated October 27, 2022 (the "Rights Offering"). Each holder of Common Stock of record as of October 24, 2022 received one right for each share of Common Stock, and each right entitled the holder of Common Stock to purchase 9.5151 shares of Common Stock at the subscription price of $0.50 per whole share.

Read SEC document
October 12, 2022 Filed Oct 14, 2022 20:05 UTC Eargo, Inc. EAR · Entity 94112 GrantStock Options (Right to Buy) · Derivative 74,074 $0.00 Strike: $0.70 $0.00
Disclosure

SEC source: 0000899243-22-033643 · doc4.xml · derivative · entry 1

Hughes Douglas J. · CIK 0001710863 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 74,074

Underlying: Common Stock · 74,074 shares

Expires 2032-10-11

F1 · derivative.exercise_date: The Stock Option vests and becomes exercisable as to 1/12th of the underlying shares on each monthly anniversary of the date of the grant, provided, that if the Company's annual meeting immediately following the date of grant takes place prior to the first anniversary of the date of grant, the Stock Option will vest and become exercisable immediately prior to the Company's annual meeting following the date of grant, subject to the Reporting Person's continued service through the applicable vesting date.

Read SEC document
August 23, 2022 Filed Aug 25, 2022 23:36 UTC Eargo, Inc. EAR · Entity 94112 GrantStock Options (Right to Buy) · Derivative 74,805 $0.00 Strike: $2.48 $0.00
Disclosure

SEC source: 0000899243-22-029777 · doc4.xml · derivative · entry 1

Hughes Douglas J. · CIK 0001710863 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 74,805

Underlying: Common Stock · 74,805 shares

Expires 2032-08-22

F1 · derivative.exercise_date: The Stock Option vests and becomes exercisable as to 1/12th of the underlying shares on each monthly anniversary of November 9, 2021, subject to the Reporting Person's continued service through the applicable vesting date.

Read SEC document
August 17, 2022 Filed Aug 19, 2022 20:41 UTC Immunovant, Inc. IMVT · Entity 3632 GrantStock Option (right to buy) · Derivative 31,668 $0.00 Strike: $4.99 $0.00
Disclosure

SEC source: 0001764013-22-000091 · wf-form4_166094167115623.xml · derivative · entry 2

Hughes Douglas J. · CIK 0001710863 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 31,668

Underlying: Common Stock · 31,668 shares

Expires 2032-08-17

F3 · derivative.exercise_date: The shares underlying the options vest one year after the date of grant on August 17, 2023, subject to the Reporting Person's continuous service to the Issuer as of such date.

Read SEC document
August 17, 2022 Filed Aug 19, 2022 20:41 UTC Immunovant, Inc. IMVT · Entity 3632 GrantCommon Stock 21,059 $0.00 $0.00
Disclosure

SEC source: 0001764013-22-000091 · wf-form4_166094167115623.xml · nonDerivative · entry 1

Hughes Douglas J. · CIK 0001710863 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 101,232

F1 · security: Represents the number of shares underlying restricted stock units awards ("RSUs").

F2 · shares: The RSUs vest in their entirety one year after the date of grant on August 17, 2023, subject to the Reporting Person's continued service to the Issuer as of such date; provided that the Reporting Person may elect to defer settlement of the RSUs upon vesting, subject to the requirements of Rule 409A.

Read SEC document
January 10, 2022 Filed Jan 12, 2022 22:00 UTC Immunovant, Inc. IMVT · Entity 3632 GrantStock Option (right to buy) · Derivative 71,492 $0.00 Strike: $7.94 $0.00
Disclosure

SEC source: 0001764013-22-000017 · wf-form4_164202480829515.xml · derivative · entry 2

Hughes Douglas J. · CIK 0001710863 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 208,973

Underlying: Common Stock · 71,492 shares

Expires 2032-01-10

F3 · derivative.exercise_date: Shares underlying the options vest over a period of two years, in a series of eight successive equal installments from the date of the award, subject to the Reporting Person providing continuous service to the Issuer as of each such date.

Read SEC document
January 10, 2022 Filed Jan 12, 2022 22:00 UTC Immunovant, Inc. IMVT · Entity 3632 GrantCommon Stock 21,726 $0.00 $0.00
Disclosure

SEC source: 0001764013-22-000017 · wf-form4_164202480829515.xml · nonDerivative · entry 1

Hughes Douglas J. · CIK 0001710863 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 80,173

F1 · security: Represents the number of shares underlying restricted stock units awards ("RSUs").

F2 · shares: The RSUs vest over a period of two years, in a series of eight successive equal installments from the date of the award, subject to the Reporting Person providing continuous service to the Issuer as of each such date.

Read SEC document
August 27, 2021 Filed Aug 30, 2021 13:08 UTC Immunovant, Inc. IMVT · Entity 3632 PurchaseCommon Stock 18,247 $8.24 $150,355.28
Disclosure

SEC source: 0001764013-21-000092 · wf-form4_163032892005129.xml · nonDerivative · entry 1

Hughes Douglas J. · CIK 0001710863 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 58,447

F1 · price: The price reported is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $8.22 - $8.24, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote to this Form 4.

Read SEC document
April 27, 2021 Filed Apr 28, 2021 21:14 UTC Eargo, Inc. EAR · Entity 94112 SaleCommon Stock 1,500 $55.00 $82,500.00
Disclosure

SEC source: 0000899243-21-017193 · doc4.xml · nonDerivative · entry 1

Hughes Douglas J. · CIK 0001710863 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 35,709

F1 · kind: The transaction was made pursuant to the terms of a 10b5-1 plan in effect at the time of sale of the shares.

Read SEC document
March 19, 2021 Filed Mar 23, 2021 12:52 UTC Immunovant, Inc. IMVT · Entity 3632 GrantStock Option (right to buy) · Derivative 23,300 $0.00 Strike: $17.00 $0.00
Disclosure

SEC source: 0001764013-21-000042 · wf-form4_161650393243276.xml · derivative · entry 2

Hughes Douglas J. · CIK 0001710863 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 23,300

Underlying: Common Stock · 23,300 shares

Expires 2031-03-19

F2 · derivative.exercise_date: The shares underlying the options vest one year after the date of grant on March 19, 2022, subject to the Reporting Person's continuous service to the Issuer as of such date.

Read SEC document
March 19, 2021 Filed Mar 23, 2021 12:52 UTC Immunovant, Inc. IMVT · Entity 3632 GrantCommon Stock 15,500 $0.00 $0.00
Disclosure

SEC source: 0001764013-21-000042 · wf-form4_161650393243276.xml · nonDerivative · entry 1

Hughes Douglas J. · CIK 0001710863 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 40,200

F1 · shares: Represents the number of shares underlying restricted stock unit awards ("RSUs") granted to the Reporting Person pursuant to a non-employee director grant. Each RSU represents the contingent right to receive one share of common stock of the Issuer. The RSUs vest in their entirety one year after the date of grant on March 19, 2022, subject to the Reporting Person's continued service to the Issuer as of such date; provided that the Reporting Person may elect to defer settlement of the RSUs upon vesting, subject to the requirements of Rule 409A.

Read SEC document
October 20, 2020 Filed Oct 22, 2020 23:29 UTC Eargo, Inc. EAR · Entity 94112 ConversionSeries C Preferred Stock · Derivative 33,259 $0.00 $0.00
Disclosure

SEC source: 0000899243-20-029075 · doc4.xml · derivative · entry 2

Hughes Douglas J. · CIK 0001710863 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 37,209 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: The Series C Preferred Stock automatically converted into shares of Common Stock on a 1:1.118772093 basis immediately prior to the completion of the Issuer's initial public offering of Common Stock and had no expiration date.

F1 · derivative.exercise_date: The Series C Preferred Stock automatically converted into shares of Common Stock on a 1:1.118772093 basis immediately prior to the completion of the Issuer's initial public offering of Common Stock and had no expiration date.

F1 · derivative.expiration_date: The Series C Preferred Stock automatically converted into shares of Common Stock on a 1:1.118772093 basis immediately prior to the completion of the Issuer's initial public offering of Common Stock and had no expiration date.

Read SEC document
October 20, 2020 Filed Oct 22, 2020 23:29 UTC Eargo, Inc. EAR · Entity 94112 ConversionCommon Stock 37,209 Not disclosed Not disclosed
Disclosure

SEC source: 0000899243-20-029075 · doc4.xml · nonDerivative · entry 1

Hughes Douglas J. · CIK 0001710863 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 37,209

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: The Series C Preferred Stock automatically converted into shares of Common Stock on a 1:1.118772093 basis immediately prior to the completion of the Issuer's initial public offering of Common Stock and had no expiration date.

Read SEC document
May 15, 2020 Filed May 18, 2020 12:42 UTC Immunovant, Inc. IMVT · Entity 3632 GrantStock Option (right to buy) · Derivative 37,000 $0.00 Strike: $19.01 $0.00
Disclosure

SEC source: 0001209191-20-029936 · doc4.xml · derivative · entry 2

Hughes Douglas J. · CIK 0001710863 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 37,000

Underlying: Common Stock · 37,000 shares

Expires 2030-05-14

F2 · derivative.exercise_date: The shares underlying the option vest in eight equal quarterly installments measured from May 15, 2020, subject to the Reporting Person providing continuous service to the Issuer as of each such date.

Read SEC document
May 15, 2020 Filed May 18, 2020 12:42 UTC Immunovant, Inc. IMVT · Entity 3632 GrantCommon Stock 24,700 $0.00 $0.00
Disclosure

SEC source: 0001209191-20-029936 · doc4.xml · nonDerivative · entry 1

Hughes Douglas J. · CIK 0001710863 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 24,700

F1 · shares: Represents the number of shares underlying restricted stock units awards ("RSUs") pursuant to a non-employee director grant. Each RSU represents the contingent right to receive one share of common stock of the Issuer. The RSUs vest in two equal annual installments on May 15, 2021 and May 15, 2022, subject to the Reporting Person's continued service to the Issuer as of each such date; provided that each director may elect to defer settlement of the RSUs upon vesting, subject to Rule 409A regulation.

F1 · price: Represents the number of shares underlying restricted stock units awards ("RSUs") pursuant to a non-employee director grant. Each RSU represents the contingent right to receive one share of common stock of the Issuer. The RSUs vest in two equal annual installments on May 15, 2021 and May 15, 2022, subject to the Reporting Person's continued service to the Issuer as of each such date; provided that each director may elect to defer settlement of the RSUs upon vesting, subject to Rule 409A regulation.

Read SEC document
December 18, 2019 Filed Dec 20, 2019 21:53 UTC Immunovant, Inc. IMVT · Entity 3632 GrantStock Option (right to buy) · Derivative 77,181 Not disclosed Strike: $8.43 Not disclosed
Disclosure

SEC source: 0001209191-19-061590 · doc4.xml · derivative · entry 1

Hughes Douglas J. · CIK 0001710863 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 77,181

Underlying: Common Stock · 77,181 shares

Expires 2029-11-19

F2 · price: In connection with the share exchange transaction pursuant to which Health Sciences Acquisitions Corporation ("HSAC") acquired 100% of the issued and outstanding shares of Immunovant Sciences Ltd., the option to purchase 157,812 shares of Immunovant Sciences Ltd. at exercise price of $4.12 per share, was assumed by HSAC and converted into an option to purchase shares of the Issuer (formerly known as HSAC).

F1 · derivative.exercise_date: This stock option vests over a period of three years, with 1/3 of the shares underlying the option vesting on each of the first, second and third anniversaries of the vesting commencement date.

Read SEC document

Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.